|Bid||9.10 x 100|
|Ask||11.05 x 100|
|Day's Range||9.20 - 9.60|
|52 Week Range||5.50 - 13.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2018 - Mar 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.33|
NEW YORK, Jan. 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Editas ...
DALLAS and FORT WORTH, Texas, Jan. 10, 2018-- Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release products using its ...
DALLAS and FORT WORTH, Texas, Nov. 28, 2017-- Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release products using its ...
On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 58 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closing price of Neos shares. PDL is confident its proposal represents fair value for the Company and offers certain and compelling value for Neos shareholders.
LONDON, UK / ACCESSWIRE / September 19, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Neos Therapeutics, Inc. (NASDAQ: NEOS ), following which we ...
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Today we've highlighted five stocks that are currently trading for under $10 per share. These stocks are also showing signs for solid growth throughout 2017, and all of them currently hold a Zacks Rank #1 (Strong Buy).
Cardiome (CRME) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
The Grand Prairie, Texas-based company said it had a loss of 83 cents per share. The pharmaceutical company posted revenue of $4.9 million in the period. Neos Therapeutics shares have risen 16 percent ...
NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Neos Therapeutics, Inc. (NASDAQ: NEOS ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 8:30 AM ...
Shire has won U.S. approval for a long-acting attention deficit drug aimed at adolescents and adults, boosting its stock of medicines for the cognitive condition that affects millions of children and is being diagnosed more in older people. The U.S. Food and Drug Administration (FDA) green light for Mydayis follows good results for Shire's new hereditary angioedema drug and helps offset the setback of early generic competition to a Shire drug for ulcerative colitis. Shares in Dublin-based Shire rose 1.5 percent by 0800 GMT in London on Wednesday following the overnight FDA news.